Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens

Cytokine

Volumn 8, Issue 1, 1996, Pages 42-48

  Roilides, Emmanuel ^a,b   Lyman, Caron A ^a   Mertins, Susan D ^a   Cole, David J ^a,c   Venzon, David ^a   Pizzo, Philip A ^a   Chanock, Stephen J ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c MUSC Medical Center   (United States)

Author keywords

Aspergillus; Candida; M CSF; Monocyte; Staphylococcus

Indexed keywords

COLONY STIMULATING FACTOR 1; FORMYLMETHIONYLLEUCYLPHENYLALANINE; RECOMBINANT COLONY STIMULATING FACTOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ADULT; ADVANCED CANCER; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; GENE EXPRESSION; HUMAN; MONOCYTE; NORTHERN BLOTTING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; BACTERIA (MICROORGANISMS); CANDIDA; CANDIDA ALBICANS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0029879957     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1996.0006     Document Type: Article

References (30)

1. Walsh TJ (1990) Invasive aspergillosis in patients with neo-plastic diseases. Sem Resp Infect 5:111-122.
2. Pizzo PA, Rubin M, Freifeld A, Walsh TJ (1991) The child with cancer and infection. II. Nonbacterial infections. J Pediatr 119:845-857.
3. Walsh TJ, Pizzo PA (1988) Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 7:460-475.
4. Pizzo PA, Rubin M, Freifeld A, Walsh TJ (1991) The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 119:679-694.
5. Roilides E, Pizzo PA (1992) Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 15:508-524.
6. Khwaja A, Johnson B, Addiso IE, Yong K, Ruthen K, Abramson S, Linch DC (1991) In vivo effects of macrophage colony-stimulating factor on human monocyte function. Br J Haematol 77:25-31.
7. Wing EJ, Ampel NM, Waheed A, Shadduck RK (1985) Macrophage colony-stimulating factor (M-CSF) enhances the capacity of murine macrophages to secrete oxygen reduction products. J Immunol 135:2052-2056.
8. Magee DM, Wing EJ, Ampel NM, Waheed A, Shadduck RK (1987) Macrophage colony-stimulating factor enhances the expression of Fc receptors on murine peritoneal macrophages. Immunology 62:373-378.
9. Cheers C, Hill M, Haigh AM, Stanley ER (1989) Stimulation of macrophage phagocytic but not bactericidal activity by colony-stimulating factor 1. Infect Immun 57:1512-1516.
10. Karbassi A, Becker JM, Foster JS, Moore RN (1987) Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: Evidence for augmented expression of mannose receptors. J Immunol 139:417-421.
11. Cenci E, Bartocci A, Puccetti P, Mocci S, Stanely ER, Bistoni F (1991) Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun 59:868-872.
12. Wang M, Friedman H, Djeu JY (1989) Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF); IL-3, granulocyte-macrophage-CSF, and macrophage-CSF. J Immunol 143:671-677.
13. Newman SL, Gootee L (1992) Colony-stimulating factors activate human macrophages to inhibit intracellular growth of Histoplasma capsulatum yeasts. Infect Immun 60:4593-4597.
14. Brummer E, Stevens DA (1994) Effects of macrophage colony-stimulating factor (M-CSF) on macrophage morphology, phagocytosis, and intracellular multiplication of Histoplasma capsulatum. Int J Immunopharmac 16:171-176.
15. Nemunaitis J, Meyers JD, Buckner D, Shannon-Dorcy K, Mori M, Shulman H, Bianco JA, Higano CS, Groves E, Storb R, Hansen J, Appelbaum FR, Singer JW (1991) Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood. 78:907-913.
16. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, Meyers JD, Owens A, Day R, Ando D, O'Neill C, Buckner D, Singer JW (1993) Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 82: 1422-1427.
17. Roilides E, Sein T, Holmes A, Chanock S, Blake C, Pizzo PA, Walsh TJ (1995) Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis (accepted).
18. Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim Hl; Levin RD, Pogrebniak HW (1994) Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J Natl Cancer Inst 86:39-45.
19. Timony G, Bree A, Metzger M (1990) Pharmacokinetics of recombinant human macrophage-colony stimulating factor (rhM-CSF). Blood 76:169a.
20. Klebanoff SJ, Hamon CB (1975) Antimicrobial systems of mononuclear phagocytes. In Van Furth R (ed.) Mononuclear Phagocytes in Immunity, Infection and Pathology, Blackwell Scientific Publications, Oxford, pp 507-531.
21. Diamond RD, Huber E, Haudenschild CC (1983) Mechanisms of destruction of Aspergillus fumigatus hyphae mediated by human monocytes. J Infect Dis. 147:474-483.
22. Green S, Hamilton JA, Uhlinger DJ, Phillips WA (1994) Expression of p47-phox and p67-phox proteins in murine bone marrow-derived macrophages: Enhancement by lipopolysaccharide and tumor necrosis factor alpha but not colony stimulating factor 1. J Leukoc Biol. 55:530-535.
23. Sakurai T, Suzu S, Yamada M, Yanai N, Kawashima T, Hatake K, Takaku F, Motoyoshi K (1994) Induction of tumor necrosis factor in mice by recombinant human macrophage colony-stimulating factor. Jpn J Cancer Res 85:80-85.
24. Motoyoshi K, Yosida K, Hatake K, Saito M, Miura Y, Yanai N, Yamada M, Kawasima T, Wong GG, Temple PA, Leary AC, Wite-Giannoti JS, Fujisawa M, Yuo A, Okabe T, Takaku F (1989) Recombinant and native human urinary colony-stimulating factor directly augments granulocyte-macrophage colony-stimulating factor production of human peripheral blood monocytes. Exp Hematol 17:68-71.
25. Moore RN, Oppenheim JJ, Farrar JJ, Carter CS, Waheed A, Shadduck RK (1980) Production of lymphocyte-activating factor (interleukin 1) by macrophages activated with colony-stimulating factors. J Immunol 125: 1302-1305.
26. Falk LA, Wahl LM, Vogel SN (1988) Analysis of Ia antigen expression in macrophages derived from bone marrow cells cultured in granulocyte-macrophage colony-stimulating factor or macrophage colony-stimulating factor. J Immunol 140:2652-2660.
27. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Granulocyte colony-stimulating factor and interferon-g enhance the oxidative responses and the damage caused by human neutrophils to Aspergillus fumigatus hyphae in vitro. Infect Immun. 61:1185, 1993.
28. Massey V (1959) The microestimation of succinate and the extinction coefficient of cytochrome c. Biochim Biophys Acta 34:255-256.
29. Levitz SM, Diamond RD (1985) A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis 152:938-945.
30. Farrell RE (1993) RNA Methodologies: A Laboratory Guide for Isolation and Characterization, Academic Press, San Diego.